These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 18523448)
1. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Osborn MJ; McElmurry RT; Peacock B; Tolar J; Blazar BR Mol Ther; 2008 Aug; 16(8):1459-66. PubMed ID: 18523448 [TBL] [Abstract][Full Text] [Related]
2. Targeting of the CNS in MPS-IH Using a Nonviral Transferrin-α-l-iduronidase Fusion Gene Product. Osborn MJ; McElmurry RT; Peacock B; Tolar J; Blazar BR Mol Ther; 2008 Aug; 16(8):1459-1466. PubMed ID: 28182871 [TBL] [Abstract][Full Text] [Related]
3. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973 [TBL] [Abstract][Full Text] [Related]
4. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I. Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595 [TBL] [Abstract][Full Text] [Related]
5. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900 [TBL] [Abstract][Full Text] [Related]
6. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883 [TBL] [Abstract][Full Text] [Related]
7. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Ou L; Przybilla MJ; Koniar B; Whitley CB Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892 [TBL] [Abstract][Full Text] [Related]
8. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Aronovich EL; Bell JB; Khan SA; Belur LR; Gunther R; Koniar B; Schachern PA; Parker JB; Carlson CS; Whitley CB; McIvor RS; Gupta P; Hackett PB Mol Ther; 2009 Jul; 17(7):1136-44. PubMed ID: 19384290 [TBL] [Abstract][Full Text] [Related]
9. Correction of mucopolysaccharidosis type I fibroblasts by retroviral-mediated transfer of the human alpha-L-iduronidase gene. Anson DS; Bielicki J; Hopwood JJ Hum Gene Ther; 1992 Aug; 3(4):371-9. PubMed ID: 1525210 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease. Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583 [TBL] [Abstract][Full Text] [Related]
14. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016 [TBL] [Abstract][Full Text] [Related]
15. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948 [TBL] [Abstract][Full Text] [Related]
16. Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. Boado RJ; Pardridge WM Mol Pharm; 2017 Apr; 14(4):1271-1277. PubMed ID: 28279069 [TBL] [Abstract][Full Text] [Related]
17. Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase. El-Amouri SS; Dai M; Han JF; Brady RO; Pan D Mol Ther; 2014 Dec; 22(12):2028-2037. PubMed ID: 25088464 [TBL] [Abstract][Full Text] [Related]
18. Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice. Bidone J; Schuh RS; Farinon M; Poletto É; Pasqualim G; de Oliveira PG; Fraga M; Xavier RM; Baldo G; Teixeira HF; Matte U Int J Pharm; 2018 Sep; 548(1):151-158. PubMed ID: 29940298 [TBL] [Abstract][Full Text] [Related]
19. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053 [TBL] [Abstract][Full Text] [Related]
20. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice. Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]